<i>TP53</i> and Prognosis in mCRPC Survival: Biology or Coincidence?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30610102.
- Also identified by DOI 10.1158/1078-0432.CCR-18-3401.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cell-free circulating tumor DNA (ctDNA) or circulating tumor cell (CTC) assays are potentially powerful in the treatment of metastatic castration-resistant prostate cancer (mCRPC). A new study suggests that mutation of TP53 supersedes AR in predicting mCRPC survival. A role for TP53 mutation as a driver for mCRPC remains unexplored.See related article by De Laere et al., p. 1766.
Medical subject headings
- Neoplastic Cells, Circulating
- Prostatic Neoplasms, Castration-Resistant